Christoph Röllig, Martin Bornhäuser, Michael Kramer, Christian Thiede, Anthony D Ho, Alwin Krämer, Kerstin Schäfer-Eckart, Hannes Wandt, Mathias Hänel, Hermann Einsele, Walter E Aulitzky, Norbert Schmitz, Wolfgang E Berdel, Matthias Stelljes, Carsten Müller-Tidow, Utz Krug, Uwe Platzbecker, Martin Wermke, Claudia D Baldus, Stefan W Krause, Friedrich Stölzel, Malte von Bonin, Markus Schaich, Hubert Serve, Johannes Schetelig, Gerhard Ehninger
PURPOSE: The presence of a mutated nucleophosmin-1 gene (NPM1(mut)) in acute myeloid leukemia (AML) is associated with a favorable prognosis. To assess the predictive value with regard to allogeneic stem-cell transplantation (SCT), we compared the clinical course of patients with NPM1(mut) AML eligible for allogeneic SCT in a donor versus no-donor analysis. PATIENTS AND METHODS: Of 1,179 patients with AML (age 18 to 60 years) treated in the Study Alliance Leukemia AML 2003 trial, we identified all NPM1(mut) patients with an intermediate-risk karyotype...
February 10, 2015: Journal of Clinical Oncology